
Securities & Capital Markets
Viewpoints
Filter by:
Impact of DEI-Related Executive Orders on Disclosures in Recent Public Company Annual Reports
February 27, 2025 | Blog | By Dina Sebrow, Anne Bruno
President Trump’s executive orders aimed at Diversity, Equity and Inclusion (DEI) programs and policies, including the executive order titled “Ending Illegal Discrimination and Restoring Merit Based Opportunity” (Executive Order 14173), are impacting the way publicly traded companies approach their DEI-related disclosures. Although enforcement of the executive orders was recently temporarily halted (as we wrote about here), as calendar year end public companies begin to file their Form 10-K Annual Reports for the fiscal year ended December 31, 2024, we have seen, and expect to continue to see, a shift in new DEI disclosures as compared to prior years. Companies are paying consideration to whether they want to include such disclosures, how comprehensive such disclosures should be, and what language should be employed to strike an appropriate balance.
SEC Adopts Final Cybersecurity Rules for Public Companies
August 1, 2023 | Blog | By Cynthia Larose, John Condon, Michael Katz, Stefan Jović
The SEC adopted its final rules and amendments concerning cybersecurity risk management, strategy, governance, and incident disclosure (the “Final Rule”) on July 26, 2023. In this article we highlight some of the principal changes to the cybersecurity rules first proposed by the SEC more than 16 months prior.
SEC Adopts Amendments to Rule 10b5-1 Insider Trading Arrangements
December 27, 2022 | Blog | By Anne Bruno, Page R. Hubben
Financing Options for Life Sciences Companies in 2022
March 21, 2022 | Blog
Public and private life science companies have multiple options available for capital-raising. Here are a few to be considered.